Inclusion Criteria:

- Patients older than 18 years of age.

- Histological confirmed diagnosis of a prostate adenocarcinoma, melanoma or colon
cancer

- At least one measurable site of disease as evidenced by CT or MRI, RECIST criteria in
soft tissue OR lymph nodes and OR tumor markers as appropriate

- Rising PSA in 3 consecutive weeks taken at least one week apart with a value of at
least 5 ng/mL

- Testosterone that is less than 50 ng/dL in prostate patients

- Prostate cancer patients receiving radiation therapy that is less than 30% of
pelvic/total bone mass and where acute radiation toxicity is resolved

- ECOG Performance status 0- 2

- WBC > 1,500 cells/mm3, hemoglobin > 9 g/dL, and platelets > 100,000 cells/mm3 and <
500,000 cells/mm3

- Adequate renal function: serum creatinine < 2.0 mg/dL, or CCT>= 50 ml/min

- Life expectancy of at least 3 months

- Willing to participate in a 6 month follow-up

- Female patients of child-bearing potential must have negative pregnancy test within 7
days before initiation of study drug dosing. Post menopausal women must be
amenorrheic for at least 12 months to be considered of non- childbearing potential.
Male and female patients of reproductive potential must agree to employ an effective
barrier method of birth control throughout the study and for up to 3 months following
discontinuation of study drug.

- Patients who have given written informed consent

Exclusion Criteria:

- Patients suffering from primary or metastatic brain or spinal tumor.

- Patients with known sensitivity to any of the components of the IVIG formulation
excipients.

- IgA levels <=60mg/dl .

- Treatment with IVIG 6 months prior to study start

- Patients that are with known seropositivity for HIV or with a known diagnosis of
human immunodeficiency virus (HIV) infection. (AIDS)

- Patients with significant diseases, active infection or uncontrolled medical
condition (e.g., pulmonary, neurological, cardiovascular, gastrointestinal,
genitourinary) considered high risk for investigational new drug treatment/ who in
the opinion of the investigator would be excluded from the study

- Female patients who are pregnant or breast-feeding.

- Patient has a severe and/or uncontrolled renal failure.

- Patient has known chronic liver disease (i.e., chronic active hepatitis, and
cirrhosis).

- Patient with any significant history of non-compliance to medical regimens or with
inability to grant reliable informed consent and who in the opinion of investigator,
are unlikely to comply with the study protocol

- Patients who are currently participating or have participated in another clinical
trial in the last 30 days.

- Patients who have undergone chemotherapy in the last 4 weeks

- Patients who are being treated with antibiotic treatment for an active infection